Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 388

Similar articles for PubMed (Select 12244597)

1.

CD8+ T-cell immunity to HIV infection.

Piazza P, Fan Z, Rinaldo CR Jr.

Clin Lab Med. 2002 Sep;22(3):773-97. Review.

PMID:
12244597
2.

Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.

Oxenius A, Price DA, Günthard HF, Dawson SJ, Fagard C, Perrin L, Fischer M, Weber R, Plana M, García F, Hirschel B, McLean A, Phillips RE.

Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13747-52. Epub 2002 Oct 7.

3.

Residual HIV-specific CD4 and CD8 T cell frequencies after prolonged antiretroviral therapy reflect pretreatment plasma virus load.

Oxenius A, Price DA, Dawson SJ, Günthard HF, Fischer M, Perrin L, Ramirez E, Fagard C, Hirschel B, Scullard G, Weber JN, McLean AR, Phillips RE; Swiss HIV cohort study.

AIDS. 2002 Nov 22;16(17):2317-22.

PMID:
12441804
4.

Low blood CD8+ T-lymphocytes and high circulating monocytes are predictors of HIV-1-associated progressive encephalopathy in children.

Sánchez-Ramón S, Bellón JM, Resino S, Cantó-Nogués C, Gurbindo D, Ramos JT, Muñoz-Fernández MA.

Pediatrics. 2003 Feb;111(2):E168-75.

PMID:
12563091
5.

Cytotoxic T lymphocytes and viral evolution in primary HIV-1 infection.

Price DA, O'callaghan CA, Whelan JA, Easterbrook PJ, Phillips RE.

Clin Sci (Lond). 1999 Dec;97(6):707-18. Review.

PMID:
10585898
6.

Functional and genetic integrity of the CD8 T-cell repertoire in advanced HIV infection.

Gamberg JC, Bowmer MI, Trahey JC, Campbell CM, Pardoe I, Grant MD.

AIDS. 1999 Oct 22;13(15):2043-53.

PMID:
10546856
7.

HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection.

Ruiz L, Carcelain G, Martínez-Picado J, Frost S, Marfil S, Paredes R, Romeu J, Ferrer E, Morales-Lopetegi K, Autran B, Clotet B.

AIDS. 2001 Jun 15;15(9):F19-27.

PMID:
11416734
8.

Selective depletion of high-avidity human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cells after early HIV-1 infection.

Lichterfeld M, Yu XG, Mui SK, Williams KL, Trocha A, Brockman MA, Allgaier RL, Waring MT, Koibuchi T, Johnston MN, Cohen D, Allen TM, Rosenberg ES, Walker BD, Altfeld M.

J Virol. 2007 Apr;81(8):4199-214. Epub 2007 Feb 7.

9.

Dynamics of T cells subsets and lymphoproliferative responses during structured treatment interruption cycles and after definitive interruption of HAART in early chronic HIV type-1-infected patients.

Libois A, López A, Garcia F, Castro P, Maleno MJ, García A, Climent N, Arnedo M, Gallart T, Gatell JM, Plana M.

AIDS Res Hum Retroviruses. 2006 Jul;22(7):657-66.

PMID:
16831090
10.

Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3.

Plana M, Garcia F, Oxenius A, Ortiz GM, Lopez A, Cruceta A, Mestre G, Fumero E, Fagard C, Sambeat MA, Segura F, Miró JM, Arnedo M, Lopalcos L, Pumarola T, Hirschel B, Phillips RE, Nixon DF, Gallart T, Gatell JM.

J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):791-9.

PMID:
15213562
11.

De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection.

Allen TM, Yu XG, Kalife ET, Reyor LL, Lichterfeld M, John M, Cheng M, Allgaier RL, Mui S, Frahm N, Alter G, Brown NV, Johnston MN, Rosenberg ES, Mallal SA, Brander C, Walker BD, Altfeld M.

J Virol. 2005 Oct;79(20):12952-60.

12.
13.

Correlates of antiviral immune restoration in acute and chronic HIV type 1 infection: sustained viral suppression and normalization of T cell subsets.

Dyer WB, Kuipers H, Coolen MW, Geczy AF, Forrester J, Workman C, Sullivan JS.

AIDS Res Hum Retroviruses. 2002 Sep 20;18(14):999-1010.

PMID:
12396452
14.

AIDS vaccine development: the long and winding road.

Garber DA, Feinberg MB.

AIDS Rev. 2003 Jul-Sep;5(3):131-9. Review.

PMID:
14598562
15.

Nanochemistry-based immunotherapy for HIV-1.

Lori F, Calarota SA, Lisziewicz J.

Curr Med Chem. 2007;14(18):1911-9. Review.

PMID:
17691933
16.

Human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T(EMRA) cells in early infection are linked to control of HIV-1 viremia and predict the subsequent viral load set point.

Northfield JW, Loo CP, Barbour JD, Spotts G, Hecht FM, Klenerman P, Nixon DF, Michaëlsson J.

J Virol. 2007 Jun;81(11):5759-65. Epub 2007 Mar 21.

17.

Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy.

Piriou E, Jansen CA, van Dort K, De Cuyper I, Nanlohy NM, Lange JM, van Oers MH, Miedema F, van Baarle D.

J Immunol. 2005 Aug 1;175(3):2010-7.

18.

Development of immunotherapeutic strategies for HIV-1.

Imami N, Hardy G, Gotch F.

Expert Opin Biol Ther. 2001 Sep;1(5):803-16. Review.

PMID:
11728216
19.

An IL-15 dependent CD8 T cell response to selected HIV epitopes is related to viral control in early-treated HIV-infected subjects.

D'Offizi G, Gioia C, Corpolongo A, Martini F, Paganelli R, Volpi I, Sacchi A, Tozzi V, Narciso P, Poccia F.

Int J Immunopathol Pharmacol. 2007 Jul-Sep;20(3):473-85.

PMID:
17880761
20.

HIV-1 Nef is preferentially recognized by CD8 T cells in primary HIV-1 infection despite a relatively high degree of genetic diversity.

Lichterfeld M, Yu XG, Cohen D, Addo MM, Malenfant J, Perkins B, Pae E, Johnston MN, Strick D, Allen TM, Rosenberg ES, Korber B, Walker BD, Altfeld M.

AIDS. 2004 Jul 2;18(10):1383-92.

PMID:
15199314
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk